Journal
TRENDS IN CARDIOVASCULAR MEDICINE
Volume 13, Issue 3, Pages 116-122Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/S1050-1738(02)00259-1
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL 63609, HL 53793] Funding Source: Medline
Ask authors/readers for more resources
The aim of therapeutic angiogenests in cardiovascular disease states is to improve myocardial and peripheral extremity-perfusion and function within ischemic regions that are not amenable to traditional modes of revascularization. Substantial roof of concept, efficacy, and safety data have emerged from numerous animal models and clinical trials that fibroblast growth factor (FGF), when administered by various delivery strategies, has a therapeutic angiogenic capacity. This initial excitement has been replaced by cautious optimism in the wake of results from larger, randomized, double-blinded placebo-controlled trials of both FGF gene and protein administration. A greater understanding of the profound placebo effect, careful patient selection, and improved endpoint assessment are factors that need to be addressed in this rapidly evolving era of molecular therapeutics. (C) 2003, Elsevier Science Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available